Our data obtained with human primary DC cultures delineate future personalized medicine combining anti-IL-17A biotherapy with (VBL- or AraC-based) chemotherapy to counteract cancer cell survival in an IL-17A-rich tolerogenic microenvironment. The gene discussed is IL17A; the disease is cancer.